• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Recent progress of genome study for anaplastic thyroid cancer.间变性甲状腺癌基因组研究的最新进展
Genomics Inform. 2013 Jun;11(2):68-75. doi: 10.5808/GI.2013.11.2.68. Epub 2013 Jun 30.
2
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.间变性甲状腺癌患者的个性化治疗:针对基因和表观遗传改变
J Clin Endocrinol Metab. 2015 Jan;100(1):35-42. doi: 10.1210/jc.2014-2803.
3
Molecular therapeutics for anaplastic thyroid cancer.间变性甲状腺癌的分子治疗。
Semin Cancer Biol. 2020 Apr;61:23-29. doi: 10.1016/j.semcancer.2020.01.005. Epub 2020 Jan 25.
4
Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.在BRAF(V600E)突变高发地区通过靶向大规模平行测序检测到的间变性甲状腺癌的基因组改变
Thyroid. 2016 May;26(5):683-90. doi: 10.1089/thy.2015.0506. Epub 2016 Apr 13.
5
Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?免疫疗法还是靶向疗法:间变性甲状腺癌未来的治疗方向是什么?
Front Oncol. 2023 Mar 17;13:1103147. doi: 10.3389/fonc.2023.1103147. eCollection 2023.
6
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.间变性甲状腺癌和滤泡状甲状腺癌中受体酪氨酸激酶、磷脂酰肌醇3激酶/蛋白激酶B及丝裂原活化蛋白激酶信号通路中高度普遍的基因改变
J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16. doi: 10.1210/jc.2008-0273. Epub 2008 May 20.
7
Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer.放疗在间变性甲状腺癌治疗中的近期趋势及潜力
Biomedicines. 2024 Jun 10;12(6):1286. doi: 10.3390/biomedicines12061286.
8
Novel treatments for anaplastic thyroid carcinoma.间变性甲状腺癌的新型治疗方法。
Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18.
9
Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines.间变性甲状腺癌细胞系中的基因组复杂性和靶向基因。
Endocr Relat Cancer. 2017 May;24(5):209-220. doi: 10.1530/ERC-16-0522. Epub 2017 Feb 24.
10
A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer.间变性甲状腺癌II期靶向治疗临床试验的系统评价
Cancers (Basel). 2019 Jul 4;11(7):943. doi: 10.3390/cancers11070943.

引用本文的文献

1
Follicular Thyroid Adenoma and Follicular Thyroid Carcinoma-A Common or Distinct Background? Loss of Heterozygosity in Comprehensive Microarray Study.滤泡性甲状腺腺瘤与滤泡性甲状腺癌——共同背景还是不同背景?综合微阵列研究中的杂合性缺失
Cancers (Basel). 2023 Jan 19;15(3):638. doi: 10.3390/cancers15030638.
2
Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View.从肿瘤抑制基因角度看甲状腺癌
Cancers (Basel). 2022 May 17;14(10):2461. doi: 10.3390/cancers14102461.
3
Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.二甲双胍与维莫非尼(PLX4032)联合作为间变性甲状腺癌分子靶向治疗的协同作用:一项体外研究
Mol Biol Rep. 2021 Nov;48(11):7443-7456. doi: 10.1007/s11033-021-06762-7. Epub 2021 Oct 30.
4
Downregulated CDH3 decreases proliferation, migration, and invasion in thyroid cancer.下调的CDH3可降低甲状腺癌的增殖、迁移和侵袭能力。
Am J Transl Res. 2020 Jun 15;12(6):3057-3067. eCollection 2020.
5
Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells.阿贝西利(CDK4/6抑制剂)阻断可诱导人间变性甲状腺癌细胞产生细胞毒性。
Rep Biochem Mol Biol. 2020 Jan;8(4):438-445.
6
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.间变性甲状腺癌:从临床病理学到遗传学和先进治疗。
Nat Rev Endocrinol. 2017 Nov;13(11):644-660. doi: 10.1038/nrendo.2017.76. Epub 2017 Jul 14.
7
Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.基于基因组的精准医学改善间变性甲状腺癌的预后。
J Oncol. 2014;2014:936285. doi: 10.1155/2014/936285. Epub 2014 Sep 7.
8
Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer.甲状腺未分化癌的研究进展:最具侵袭性的甲状腺癌的形态学、分子和遗传学特征。
Int J Endocrinol. 2014;2014:790834. doi: 10.1155/2014/790834. Epub 2014 Aug 21.
9
Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.间变性甲状腺癌:当前的治疗方法和潜在的新治疗选择,重点是 TfR1/CD71。
Int J Endocrinol. 2014;2014:685396. doi: 10.1155/2014/685396. Epub 2014 Jul 1.
10
Autophagy: A potential target for thyroid cancer therapy (Review).自噬:甲状腺癌治疗的潜在靶点(综述)
Mol Clin Oncol. 2014 Sep;2(5):661-665. doi: 10.3892/mco.2014.305. Epub 2014 Jun 6.

本文引用的文献

1
Molecular pathogenesis and mechanisms of thyroid cancer.甲状腺癌的分子发病机制及机制。
Nat Rev Cancer. 2013 Mar;13(3):184-99. doi: 10.1038/nrc3431.
2
Perspectives of integrative cancer genomics in next generation sequencing era.下一代测序时代综合癌症基因组学的展望
Genomics Inform. 2012 Jun;10(2):69-73. doi: 10.5808/GI.2012.10.2.69. Epub 2012 Jun 30.
3
Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells.环磷酸腺苷反应元件调节剂抑制甲状腺癌细胞中钠碘转运体基因的启动子活性。
Thyroid. 2012 May;22(5):487-93. doi: 10.1089/thy.2011.0360. Epub 2012 Apr 17.
4
Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.BRAF V600E 突变在甲状腺癌细胞中引起的全基因组基因甲基化改变。
Endocr Relat Cancer. 2011 Nov 14;18(6):687-97. doi: 10.1530/ERC-11-0212. Print 2011 Dec.
5
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint.良性和恶性甲状腺疾病中的 RET/PTC 重排:临床观点。
Eur J Endocrinol. 2011 Oct;165(4):499-507. doi: 10.1530/EJE-11-0499. Epub 2011 Jul 12.
6
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.间变性甲状腺癌中存在 ALK 基因的新型致癌突变。
Cancer Res. 2011 Jul 1;71(13):4403-11. doi: 10.1158/0008-5472.CAN-10-4041. Epub 2011 May 19.
7
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.在甲状腺癌中鉴定出几种新的非 p.R132 IDH1 变体。
Eur J Endocrinol. 2010 Nov;163(5):747-55. doi: 10.1530/EJE-10-0473. Epub 2010 Aug 11.
8
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.鉴定和功能分析甲状腺癌中的异柠檬酸脱氢酶 1(IDH1)突变。
Biochem Biophys Res Commun. 2010 Mar 12;393(3):555-9. doi: 10.1016/j.bbrc.2010.02.095. Epub 2010 Feb 18.
9
Prognostic utility of BRAF mutation in papillary thyroid cancer.BRAF 突变在甲状腺乳头状癌中的预后价值。
Mol Cell Endocrinol. 2010 May 28;321(1):86-93. doi: 10.1016/j.mce.2009.10.012. Epub 2009 Oct 31.
10
International patterns and trends in thyroid cancer incidence, 1973-2002.1973年至2002年甲状腺癌发病率的国际模式与趋势
Cancer Causes Control. 2009 Jul;20(5):525-31. doi: 10.1007/s10552-008-9260-4. Epub 2008 Nov 19.

间变性甲状腺癌基因组研究的最新进展

Recent progress of genome study for anaplastic thyroid cancer.

作者信息

Lee Jieun, Hwang Jung-Ah, Lee Eun Kyung

机构信息

Cancer Genomics Branch, Research Institute, National Cancer Center, Goyang 410-769, Korea.

出版信息

Genomics Inform. 2013 Jun;11(2):68-75. doi: 10.5808/GI.2013.11.2.68. Epub 2013 Jun 30.

DOI:10.5808/GI.2013.11.2.68
PMID:23843772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3704929/
Abstract

Anaplastic thyroid cancer (ATC) belongs to the most malignant and rapidly progressive human thyroid cancers and its prognosis is very poor. Also, it shows high resistance to cancer treatments, so that effective treatment for ATC has not been found to date, and virtually all patients terminate their life rapidly after diagnosis. Although targeted treatment of genetic alterations has emerged as an extremely promising approach to human cancers, such as BRAF in metastatic melanoma, it remains unclear that how commonly genomic alterations are influenced in ATC tumorigenesis. In recent years, genome wide approaches have been exploited to find genetic alterations associated with complex diseases, including cancer. Here, we reviewed the comprehensive genetic alterations in ATC and recent approaches in the context of identifying genomic alterations associated with ATC. Since surprisingly few reports have been published on the genome wide study of ATC, this review puts emphasis on the urgent needs of genomic research for the prevention and treatment of ATC.

摘要

间变性甲状腺癌(ATC)是人类甲状腺癌中恶性程度最高、进展最快的类型,其预后很差。此外,它对癌症治疗表现出高度抗性,以至于迄今为止尚未找到针对ATC的有效治疗方法,几乎所有患者在确诊后都很快死亡。尽管针对基因改变的靶向治疗已成为治疗人类癌症极具前景的方法,如用于转移性黑色素瘤中的BRAF,但目前尚不清楚基因组改变在ATC肿瘤发生过程中的普遍程度。近年来,全基因组方法已被用于寻找与包括癌症在内的复杂疾病相关的基因改变。在此,我们综述了ATC中的全面基因改变以及在鉴定与ATC相关的基因组改变背景下的最新方法。由于关于ATC全基因组研究的报道出奇地少,本综述强调了基因组研究对于ATC预防和治疗的迫切需求。